MERIT MEDICAL SYSTEMS INC 8-K

What Happened
Merit Medical Systems, Inc. (MMSI) filed a Form 8-K on April 13, 2026 (Item 7.01) to disclose historical revenue broken out under its new product categories, "Foundational" and "Therapeutic," for the years ended December 31, 2022–2025 and for each quarter from March 31, 2024 through December 31, 2025. The data are unaudited and presented in thousands; Merit says this is for comparability and does not revise or restate previously reported consolidated financial statements. For the year ended 2025 Merit reported Foundational revenue of $1,028,540 and Therapeutic revenue of $487,366, totaling $1,515,906 (all figures in thousands), versus a 2024 total of $1,356,514 (thousands).

Key Details

• 2025 total revenue (unaudited, in thousands): $1,515,906; 2024 total: $1,356,514 — roughly an 11.8% year-over-year increase.
• Quarterly totals (2025 vs 2024): Q1 $355,351 vs $323,508; Q2 $382,462 vs $338,003; Q3 $384,157 vs $339,845; Q4 $393,936 vs $355,158 — all quarters rose in 2025.
• Product-platform highlights for 2025 (unaudited, in thousands): Foundational — Access $588,542; OEM $167,086; Procedural Solutions $124,717; Vascular Intervention $139,997. Therapeutic — Vascular Intervention $131,457; Oncology $96,805; Cardiac Therapies $93,357; Endoscopy $72,481.
• Merit noted it is providing platform-level detail for historical context but does not intend to provide product-platform disaggregation on a recurring basis.

Why It Matters
This disclosure gives investors clearer visibility into how Merit’s revenue mixes between its two new core categories and across product platforms, showing broad revenue growth in 2025 versus 2024 and notable increases in therapeutic areas such as Cardiac Therapies and Vascular Intervention. The company stresses the figures are historical, unaudited, and not a restatement — useful for comparability but not a change to previously reported financial statements.